The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

Sponsor

Spectrum Pharmaceuticals, Inc (Industry)

Overall Status

Completed

CT.gov ID

NCT00427219

Collaborator

(none)

Enrollment

Locations

Arms

13.1

Actual Duration (Months)

5.7

Patients Per Site

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.

Condition or Disease	Intervention/Treatment	Phase
Benign Prostatic Hypertrophy	Drug: Ozarelix Drug: Placebo	Phase 2

Detailed Description

This study is to compare the improvement in symptom scores, peak flow rate and quality of life in men suffering from lower urinary tract symptoms (LUTS) secondary to Benign Prostatic Hypertrophy (BPH) following treatment with ozarelix. Ozarelix is compared to placebo and injections given 14 days apart. Patients are followed for 6 months and both safety and efficacy assessed at monthly visits. Additionally, the impact of treatment on erectile function, if any, as well as Prostate-Specific Antigen (PSA) and Testosterone levels will be monitored.

The screening period of 7 days. The duration of the study is 40 weeks, including a 28-day placebo run-in phase (eligible participants entered a placebo run-in phase in which placebo is administered twice over a 2 week period [Day -28 and Day -14] and participants are assessed to establish baseline values approximately 14 days following the second placebo injection), study drug is administered on Days 0 and 14 followed by 34 weeks of observation after the last dose of study drug.

Study Design

Study Type:

Interventional

Actual Enrollment :

74 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS) Due to Benign Prostatic Hypertrophy (BPH)

Actual Study Start Date :

Jan 23, 2007

Actual Primary Completion Date :

Feb 27, 2008

Actual Study Completion Date :

Feb 27, 2008

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Ozarelix All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received ozarelix on Day 0 and Day 14.	Drug: Ozarelix Ozarelix 15 mg will be administered IM on Day 0 and Day 14.
Placebo Comparator: Placebo All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received placebo Day 0 and Day 14.	Drug: Placebo Placebo will be administered IM on Day 0 and Day 14.

Arm

Intervention/Treatment

Experimental: Ozarelix

All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received ozarelix on Day 0 and Day 14.

Drug: Ozarelix

Ozarelix 15 mg will be administered IM on Day 0 and Day 14.

Placebo Comparator: Placebo

All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received placebo Day 0 and Day 14.

Drug: Placebo

Placebo will be administered IM on Day 0 and Day 14.

Outcome Measures

Primary Outcome Measures

Change From Baseline in International Prostate Symptom Score (IPSS) [12 weeks]
IPSS is a validated self-administered index for grading benign prostatic hyperplasia (BPH)-related signs and symptoms. It consists of a set of seven questions. A total score of 1-7 indicates mild disease, 8-19 moderate disease and 20-35 severe disease.

Secondary Outcome Measures

International Prostate Symptom Score - Quality of Life (IPSS-QOL) [36 weeks]
IPSS QOL is a disease-specific quality of life question, referred to as IPSS Question 8. Participants with an IPSS QOL of <3 at screening will be excluded from this study. The rating is as follows: 0=delighted, 1=pleased, 2=mostly satisfied, 3=mixed, 4=mostly dissatisfied, 5=unhappy, 6=terrible.
BPH Impact Index (BPHII) [36 weeks]
BPH Impact Index (BII) is used to assess the impact of BPH on various aspects of health. This 4 question self administered index uses a scoring range from 0 (best) to 13 (worst).
Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ) [36 weeks]
The self administered LUTS GAQ is a "yes" or "no" response to a question asking whether overall improvement in LUTS will be observed during the treatment period.
International Index of Erectile Function-15 (IIEF-15) [36 weeks]
International Index of Erectile Function Erectile Function Domain (IIEF-EF) will be used to assess the effect of ozarelix on erectile function in sexually active men. IIEF-EF is defined as the sum of the scores for Questions 1-5 and 15 of the IIEF questionnaire. This recall instrument is self-administered by the participant. Individual questions are graded from 1 to 5 with a maximum total score of 30. Lower IIEF-EF scores represent diminished erectile function. Men with a score of ≥ 26 are interpreted as having normal erectile function.
Maximum Urinary Flow Rate (Qmax) [36 weeks]
Qmax was measured by free flow uroflowmetry. Qmax is defined as the peak urine flow rate (measured in milliliter (mL)/second using a standard calibrated flowmeter). For a Qmax to be considered valid, the voided volume had to be at least 125 mL. The uroflowmeter is to be calibrated weekly.
Number of Participants With Adverse Events [36 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

50 Years and Older

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

All of the following questions must be answered "Yes" at Visit 1 in order for the participant to participate in the study.
Is the participant at least 50 years old?
Does the participant have clinical signs and symptoms consistent with BPH?
Does the participant have an IPSS 13 at screening (prior to placebo run in)?
Does the participant have a peak urinary flow rate (Qmax) of 4-15 milliliter/second (mL/sec) established on a voided volume of at least 125 mL?
Is the participant willing to agree not to use any other approved or experimental pharmacologic BPH treatments including alpha blockers, 5-alpha reductase inhibitors, anti-cholinergic preparations or herbal preparations at any time during the study?

Exclusion Criteria: All of the following questions must be answered "No" at Visit 1 in order for the participant to participate in the study.

Does the participant have a history of prostate cancer or a serum PSA >10 nanograms per milliliter (ng/mL)?
Has the participant had prior prostate or bladder surgery, pelvic surgery (excluding hernia repair), pelvic radiation or lower urinary tract malignancy?
Does the participant have a prevoid total bladder volume assessed by ultrasound > 550 mL?
Does the participant have a residual urine volume > 350 mL by ultrasound?

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Donald Gleason, MD	Tucson	Arizona	United States	85712
2	Jay Young, MD	Laguna Hills	California	United States	92653
3	Alexander Gershman, MD	Los Angeles	California	United States	90048
4	Stephen Auerbach, MD	Newport Beach	California	United States	92660
5	Eugene Dula, MD	Tarzana	California	United States	91356
6	Joel Kaufman, MD	Aurora	Colorado	United States	80012
7	Ira Klimberg, MD	Ocala	Florida	United States	34474
8	Joseph Williams, MD	Meridian	Idaho	United States	83642
9	Christopher Steidle, MD	Fort Wayne	Indiana	United States	46825
10	Steven Bigg, MD	Saint Louis	Missouri	United States	63136
11	Jed Kaminetsky, MD	New York	New York	United States	10016
12	William Fitch, MD	San Antonio	Texas	United States	78229
13	Gregg Eure, MD	Virginia Beach	Virginia	United States	23454